How Leadership Changes And Analyst Revisions Are Shaping Pulmonx's Valuation Story [Yahoo! Finance]
Pulmonx Corporation (LUNG)
US:NASDAQ Investor Relations:
investor.prolunginc.com/investor-relations
Company Research
Source: Yahoo! Finance
With fair value steady at $5.75 per share, a slightly higher discount rate and essentially unchanged revenue growth outlook reflect a careful balance between confidence in the Zephyr platform and caution around execution and macro headwinds. Read on to see how this evolving narrative shapes expectations from both bullish and bearish analysts, and how you can stay plugged in as future updates shift the story. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Pulmonx. ?? Bullish Takeaways Lake Street maintained its Buy rating even as it cut its Pulmonx price target to $4 from $8, signaling the firm still sees meaningful upside from current trading levels. The firm argues the stock remains attractive given the extensive clinical verification and proof of concept for Zephyr valves, as well as the broader market opportunity and new product pipeline that support a longer runway for growth. Lake Street notes that it
Show less
Read more
Impact Snapshot
Event Time:
LUNG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUNG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUNG alerts
High impacting Pulmonx Corporation news events
Weekly update
A roundup of the hottest topics
LUNG
News
- What New Catalysts Are Shifting the Pulmonx Story for Investors [Yahoo! Finance]Yahoo! Finance
- Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Pulmonx (NASDAQ:LUNG) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LUNG&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
- Pulmonx (NASDAQ:LUNG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- How Recent Shifts Are Rewriting the Story for Pulmonx [Yahoo! Finance]Yahoo! Finance
LUNG
Earnings
- 11/12/25 - Beat
LUNG
Sec Filings
- 12/10/25 - Form 3
- 12/9/25 - Form 4
- 12/8/25 - Form 144
- LUNG's page on the SEC website